Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in ...

Nano-X Imaging is a disruptive biotech investment. The AI push in the health sector is a long-term tailwind. See why we rate ...

Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and ...

Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Irhythm Technologies (IRTC – Research Report), Vir ...

It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc ...

Kingsview Wealth Management LLC lifted its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 60.3% during the ...

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...

The aggregate gross proceeds to the Company from the offering were approximately $1,050,000, before deducting the placement ...